Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.
Garraway, most recently Eli Lilly’s senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.
Horning, who joined Roche and its Genentech division nearly a decade ago and has been chief medical officer since 2014, will retire as of the end of 2019, Roche said in a statement.
She led the product development organization, oversaw late-stage clinical development, and co-chaired the committee that invests in pivotal registrational trials.
Garraway joined Lilly in 2017 as senior vice president, global development and medical affairs for the oncology division. Before that he was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals.
In 2010, Garraway, a Harvard graduate, co-founded Foundation Medicine, which provides tumor molecular information.
By John Miller
Source: Reuters
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.
